Volume 6, issue 1, December 2013
94 articles in this issue
-
-
RETRACTED ARTICLE: Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor
Authors (first, second and last of 4)
-
Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines
Authors (first, second and last of 11)
-
Fact or fiction - identifying the elusive multiple myeloma stem cell
Authors (first, second and last of 4)
-
STAT inhibitors for cancer therapy
Authors (first, second and last of 6)
This is part of 1 collection:
-
Anti-CCR7 therapy exerts a potent anti-tumor activity in a xenograft model of human mantle cell lymphoma
Authors (first, second and last of 12)
-
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
Authors (first, second and last of 5)
This is part of 1 collection:
-
miR-363-5p regulates endothelial cell properties and their communication with hematopoietic precursor cells
Authors (first, second and last of 10)
-
Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma study group
Authors (first, second and last of 20)
-
FISH+CD34+CD38- cells detected in newly diagnosed acute myeloid leukemia patients can predict the clinical outcome
Authors (first, second and last of 16)
-
-
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application
Authors (first, second and last of 20)
-
STAT3 mutations are frequent in T-cell large granular lymphocytic leukemia with pure red cell aplasia
Authors (first, second and last of 8)
-
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
Authors (first, second and last of 22)
-
-
-
Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity
Authors (first, second and last of 15)
-
Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs
Authors (first, second and last of 7)
-
Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement
Authors (first, second and last of 10)
-
G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responses
Authors (first, second and last of 8)
-
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
Authors (first, second and last of 4)
-
Stem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromes
Authors (first, second and last of 11)
-
IGF binding protein 2 is a cell-autonomous factor supporting survival and migration of acute leukemia cells
Authors (first, second and last of 6)
-
Differential responses to genotoxic agents between induced pluripotent stem cells and tumor cell lines
Authors (first, second and last of 7)
-
Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century
Authors (first, second and last of 11)
-
-
Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing
Authors (first, second and last of 10)
-
Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models
Authors (first, second and last of 20)
-
-
Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions
Authors (first, second and last of 6)
-
Proliferation inhibition and apoptosis induction of imatinib-resistant chronic myeloid leukemia cells via PPP2R5C down-regulation
Authors (first, second and last of 10)
-
High rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia A patients not undergoing immunotolerance
Authors (first, second and last of 7)
-
Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients
Authors (first, second and last of 13)
-
An evolving new paradigm: endothelial cells – conditional innate immune cells
Authors (first, second and last of 5)
-
PAX8: a sensitive and specific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy
Authors (first, second and last of 9)
-
Ibrutinib and novel BTK inhibitors in clinical development
Authors (first, second and last of 5)
This is part of 1 collection:
-
Enhanced levels of asymmetric dimethylarginine in a serum of middle age patients with myelodysplastic syndrome
Authors (first, second and last of 6)
-
-
Immunoglobulin E induces VEGF production in mast cells and potentiates their pro-tumorigenic actions through a Fyn kinase-dependent mechanism
Authors (first, second and last of 5)
-
Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy
Authors (first, second and last of 6)
-
-
Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma
Authors (first, second and last of 8)
-
Protein biomarkers distinguish between high- and low-risk pediatric acute lymphoblastic leukemia in a tissue specific manner
Authors (first, second and last of 6)
-
Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy
Authors (first, second and last of 8)
-
Signal transduction inhibitors in treatment of myelodysplastic syndromes
Authors (first, second and last of 9)
This is part of 1 collection:
-
Induction of acquired drug resistance in endothelial cells and its involvement in anticancer therapy
Authors (first, second and last of 14)
-
A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors
Authors (first, second and last of 12)
-
Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges
Authors (first, second and last of 5)
-
A phase II study of sorafenib (BAY 43–9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)
Authors (first, second and last of 10)
-
Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy?
Authors (first, second and last of 9)
